NCT02778204 - Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 5, 2017

Primary Completion Date

September 6, 2019

Study Completion Date

November 20, 2019

Conditions

HIV Infections

Interventions

DRUG

Maraviroc

8 mg/kg oral solution as a single dose.

DRUG

Maraviroc

8 mg/kg oral solution given twice daily.

Trial Locations (9)

Soweto IMPAACT CRS, Johannesburg

Umlazi CRS, Durban

Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok

Kenya Medical Research Institute / Walter Reed Project Clinical Research Center, Kericho CRS, Kericho

Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago

Univ. of Colorado Denver NICHD CRS, Aurora

Usc La Nichd Crs, Los Angeles

Lurie Children's Hospital of Chicago (LCH) CRS, Chicago

St. Jude Children's Research Hospital CRS, Memphis